ArticleMedical oncology (Northwood, London, England)2025
Fatty acid metabolic signature reveals FASN as an immunosuppressive factor in DLBCL tumor microenvironment.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Targeting fatty acid metabolism pathway represents a promising therapeutic strategy, particularly for patients with refractory or relapsed DLBCL. In this study, fatty-acid metabolism index (FMI) signature including 20 genes was constructed by univariate Cox and LASSO-Cox regression analysis using transcriptomic data from Gene Expression Omnibus database to predict overall survival of DLBCL patients. The FMI signature exhibited a negative association with anti-tumor immune response, with FMI-high patients had decreased immune cell infiltration and downregulated immune-associated signaling pathways. Based on the FMI signature, FASN was identified as the most essential gene that negatively regulated the tumor microenvironment of DLBCL. High FASN expression was associated with reduced anti-tumor immune activity, including decreased immune score, lower T-cell inflamed score, and downregulated expression of IFN molecules. Infiltration of immune cells, including CD4
Indexed as
Identifiers
41452398What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.